Acquisition Ally SystemLink, a niche HLA software provider with recent acquisition by Thermo Fisher Scientific presents a potential cross-sell or integration opportunity for Thermo Fisher customers seeking enhanced Histocompatibility and Immunogenetics capabilities.

SMB Focus With a small team size (2-10 employees) and revenue in the low millions, SystemLink represents a scalable, high-margin add-on for larger lab software ecosystems looking to expand into HLA applications without large onboarding costs.

HLA Expertise As a long-standing leader in HLA application development since 1999, SystemLink offers specialized domain expertise that can attract labs needing mature histocompatibility and immunogenetics solutions, potentially accelerating adoption for Thermo Fisher’s immune-genomics portfolio.

Digital Presence The tech stack relies on common web technologies (WordPress, jQuery, Bootstrap) and analytics, suggesting opportunities to upgrade UI/UX, expand digital marketing, and optimize customer acquisition and onboarding for a broader audience.

Funding Signal Revenue range indicates growing, but not dominant market presence; targeted outreach to mid-size and emerging labs investing in HLA capabilities could unlock channel partnerships or co-selling with larger telemetry and lab IT ecosystems.